MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

Merck (MRK) announced positive data from the waveLINE-003 study of zilovertamab vedotin, its antibody drug conjugate (ADC), showing a 56.3% objective response rate in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when combined with R-GemOx. Additionally, Merck reported encouraging safety and efficacy data from the KANDLELIT-001 study of its KRAS G12C inhibitor candidate, MK-1084, in patients with advanced KRAS G12C-mutated colorectal and non-small cell lung cancers, demonstrating antitumor activity and a manageable safety profile.

Analysis

Merck (MRK) has reported encouraging clinical data for two key oncology candidates: its first-in-class antibody drug conjugate (ADC), zilovertamab vedotin, demonstrated a 56.3% objective response rate (ORR) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when combined with R-GemOx in the waveLINE-003 study, including eight complete responses and one partial response, alongside a manageable safety profile. Simultaneously, its KRAS G12C inhibitor candidate, MK-1084, showed antitumor activity and tolerability in treating KRAS G12C-mutated colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) in the KANDLELIT-001 study. Both zilovertamab vedotin, targeting the ROR1 cell surface protein, and MK-1084 are advancing in multiple mid-to-late-stage studies, indicating a strengthening oncology pipeline for Merck. Despite these positive developments from its pipeline, Merck's stock has significantly underperformed, with shares down 22.7% year-to-date, lagging the industry's 3.6% decline, and currently holds a Zacks Rank #3 (Hold). The article contrasts this with Lexicon Pharmaceuticals (LXRX) and Chemomab Therapeutics (CMMB), both Zacks Rank #2 (Buy) stocks, which have seen narrowing loss per share estimates for 2025 and 2026, although their shares have also experienced year-to-date declines of 15.2% and 27.1% respectively.

Key Decisions for Investors

• Investors should evaluate the apparent disconnect between Merck's positive oncology pipeline developments, including the 56.3% ORR for zilovertamab vedotin, and its significant year-to-date stock underperformance of 22.7%, considering if current valuation adequately reflects these R&D advancements.
• Monitor upcoming clinical trial readouts for Merck's zilovertamab vedotin and MK-1084, as continued positive data could serve as catalysts to potentially rerate the stock, especially given its current Hold status despite promising drug candidates.
• For sector diversification or alternative biotech exposure, consider investigating Lexicon Pharmaceuticals (LXRX) and Chemomab Therapeutics (CMMB), which, despite their own share price declines, are presented with Buy ratings and improving analyst loss estimates, warranting further due diligence on their specific risk-reward profiles.